Clinical trials: NSCLC (non-small Cell Lung Cancer)
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
Cancer Panel From Blood of Lung Cancer Patients
Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making.
- Trial name
- CAPABLE (NCT03235765)
- Testing
- MACROGEN Pan Cancer Panel (Tier 2)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Stage IIIA Non-small Cell Lung Cancer
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
Phase I trial to study the effectiveness of combining carboplatin and paclitaxel, radiation therapy with gadolinium texaphyrin, and surgery in treating patients who have stage IIIA non-small cell lung cancer.
- Trial name
- NCT00005065
- Testing
- paclitaxel, carboplatin, motexafin gadolinium
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Carcinoma
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
The main purpose of this research study is to see if adding fulvestrant (Faslodex) to erlotinib (Tarceva) is effective in patients with stage IIIb/IV Non-Small Cell Lung Cancer.
- Trial name
- NCT00592007
- Testing
- Fulvestrant and Erlotinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Lyudmila Bazhenova, M.D.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Study of rSIFN-co in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, phase I study of rSIFN-co (3 times a week via subcutaneous injection for 21 days, with 1 week of washout per cycle).
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Carcinoma, Hepatocellular
- Trial name
- rSIFN-01 (NCT02387307)
- Testing
- rSIFN-co
- Where
- Singapore
- Volunteers
- 42 people
- Sponsor
- Sichuan Huiyang Life Science and Technology Corporation
Lung Cancer - Non Small Cell, EGFR Exon 19 Deletion Mutation
Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual…
- Trial name
- EGFR Lung Canc (NCT06659458)
- Testing
- blood draw, Gene sequencing
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Our Lady of the Lake Hospital
Non Small Cell Lung Cancer
Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer
Aim of the present retrospective study is to evaluate molecular factors of primary resistance to tyrosine kinase inhibitors in metastatic non small cell lung cancer (NSCLC) patients.
- Trial name
- NCT01163058
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Istituto Clinico Humanitas
Advanced Non-Small Cell Lung Cancer (NSCLC)
Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial
The goal of this clinical trial is to evaluate whether individualized sequencing of immunotherapy and chemotherapy based on immune dynamics can improve treatment outcomes in adults with advanced non-small cell lung cancer (NSCLC)…
- Trial name
- NCT07190027
- Testing
- Arm 1： Standard Synchronous Group, Arm 2：Fixed Delay Group, Arm 3： Individualized Delay Group
- Volunteers
- 246 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Lung Cancer
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether giving gefitinib after initial chemotherapy is effective in delaying the recurrence of…
- Trial name
- NCT00091156
- Testing
- gefitinib, adjuvant therapy
- Where
- 28 sites in Belgium, Cyprus and 3 more
- Volunteers
- 598 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-small Cell Lung Cancer
Perceptions on Expected Outcomes of Immunotherapy in Advanced Cancer Patients With Poor Performance Status
To better understand your feelings and expectations about immunotherapy
- Trial name
- NCT05634551
- Testing
- Questionnaires, Interview
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
Phase I, Study in Chinese NSCLC Patients
A Phase I, Open-Label, Two Parts Study to Assess the Safety, Tolerability,Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Chinese Patients with Advanced Non-Small Cell Lung Cancer who have Progressed Following…
- Trial name
- AURAChinaPK (NCT02529995)
- Testing
- AZD9291 40 mg, AZD9291 80 mg
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
NSCLC Stage IV, Brain Metastases
SRS Sequential Sindilimab in Brain Metastasis of NSLSC
A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab
- Conditions
- NSCLC Stage IV, Brain Metastases, SRS, Sintilimab
- Trial name
- NCT04180501
- Testing
- SRS sequential sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xiaorong Dong
Carcinoma, Non-Small-Cell Lung
Trial of Chemotherapy Followed by Pulsed Docetaxel and Concurrent Radiation for Non-Small Cell Lung Cancer
The University of Rochester Cancer Center (URCC) is conducting a research study at Highland Hospital and Strong Memorial of lung cancer patients whose tumors cannot be surgically removed.
- Trial name
- NCT00167401
- Testing
- docetaxel, cisplatin, radiation treatment
- Where
- United States
- Sponsor
- University of Rochester
Solid Tumors, Non-small Cell Lung Carcinoma
A Study of DS-2248 in Participants With Advanced Solid Tumors
This phase 1 clinical trial is intended to understand the safety and tolerability of a new anticancer drug in subjects with advanced solid tumors.
- Trial name
- NCT01288430
- Testing
- DS-2248
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Daiichi Sankyo
Non Small Cell Lung Cancer
Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
On this study patients will receive dasatinib, a targeted therapy, for advanced NSCLC that has progressed after previous therapy. Safety and response to dasatinib will be assessed.
- Trial name
- TOP0801 (NCT00787267)
- Testing
- Dasatinib
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Duke University
Non-Small Cell Lung Cancer
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
This phase II single-armed study will examine the clinical utility of retreating patients with osimertinib, in the third-line, following first-line treatment with osimertinib and second-line treatment with platinum and pemetrexed…
- Trial name
- OCELOT (NCT04335292)
- Testing
- Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line
- Where
- 10 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Mark Vincent
NSCLC, Stage I
Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery
This study aims to evaluate the safety and mechanisms of action of the trimodality treatment (radiotherapy, immunotherapy and surgery) in early-stage non-small cell lung cancer.
- Trial name
- NCT03446911
- Testing
- SABR, SABR + pembrolizumab
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation
This study assesses cardiovascular injury and cardiac fitness in patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) receiving model based personalized chemoradiation.
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT05010109
- Testing
- 6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Non-small Cell Lung Cancer
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05369312
- Testing
- BPI-442096
- Where
- 5 sites in China
- Volunteers
- 230 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer (NSCLC)
A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
Evaluate the efficacy and safety of neoadjuvant furmonertinib combined with anlotinib and chemotherapy in patients with resectable stage II-III EGFR mutation-positive non-small cell lung cancer.
- Trial name
- NCT06585644
- Testing
- Furmonertinib in combination with Anrotinib and chemotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China